-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics Enters Exclusive Collaboration And In-Licensing Agreement With QIMR Berghofer For First-In-Class PD-L1 Degrader Program

Benzinga·10/07/2025 12:42:56
Listen to the news

Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer immunotherapy.